01 — What we do
Molecular Cartography platform
Our Molecular Cartography platform is a groundbreaking multi-analyte, highly multiplex spatial analysis technology that enables scientists to resolve the most complex biological challenges in areas such as oncology, neuroscience, and infectious disease.
The pioneering platform produces deep contextual data sets that illuminate molecular interactions at subcellular resolution, while preserving the sample tissue. The initial applications of Resolve Biosciences’ Molecular Cartography platform deliver the highest-resolution view of transcriptomic activity and provide the ability to interrogate hundreds of genes in a single run. Future solutions will add DNA, protein, and metabolomic data layers. Unlike current approaches, Resolve Biosciences’ technology provides the required sensitivity, specificity, and workflow convenience to elucidate the cell’s complex transcriptional landscape.
The Molecular Cartography platform has been under development since 2016 and was initially available through an oversubscribed early access program.
02 — About us
The Molecular Cartography Company
We are bringing the latest advances in German precision engineering to the biotechnology field.
Together with our talented team of scientists and investors, we are poised to lead the next generation of single-cell analysis and enable scientists around the world to apply the power of Molecular Cartography to gain new insights based on the highest-resolution view of single-cell spatial biology. Resolve Biosciences is privately held and headquartered in Monheim am Rhein, Germany.
Jason T. Gammack brings more than 25 years of life sciences industry experience and has developed successful product and customer engagement strategies for some of its preeminent biotechnology brands. He recently served as Chief Commercial Officer at Inscripta, where he oversaw sales, marketing, business development, and customer support for the company’s CRISPR-enabled Onyx™ Digital Genome Engineering platform. Before that, he was Vice President of the Life Science Business at QIAGEN, where he led the life science portfolio and go-to-market strategy. Earlier in his career, Gammack developed commercialization growth strategies at Ingenuity Systems, a leading bioinformatics company acquired by QIAGEN in 2013. He has also held senior leadership roles at Sigma-Aldrich, Invitrogen/Life Technologies, Affymetrix, and Promega Corporation.
Investors
The $24 million Series A financing round was led by PS Capital Management and MasterMind Advisory Services and included participation from Alafi Capital, John Shoffner, and High Tech Gründerfonds.
The $71 million Series B financing was the latest round of funding led by Patient Square Capital and included participation from EDBI, PS Capital, Alafi Capital, and NRW.BANK, as well as other existing investors. The company has now raised more than $100 million.
03 — In the News
In the News
Resolve Biosciences Secures $71 Million Series B Financing to Accelerate Commercial Expansion to Meet Global Demand for Molecular Cartography™ Workflow
press release — October 24, 2022
Resolve Biosciences Sets New Standard for Single-Cell Spatial Analysis with Launch of Fully Automated Molecular CartographyTM Workflow
press release — June 7, 2022
Download Resources
04 — Contact us
05 — Stay informed
